177 related articles for article (PubMed ID: 7910372)
1. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates.
Stein WD; Cardarelli C; Pastan I; Gottesman MM
Mol Pharmacol; 1994 Apr; 45(4):763-72. PubMed ID: 7910372
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system.
Ramachandra M; Ambudkar SV; Gottesman MM; Pastan I; Hrycyna CA
Mol Biol Cell; 1996 Oct; 7(10):1485-98. PubMed ID: 8898356
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA.
Lincke CR; van der Bliek AM; Schuurhuis GJ; van der Velde-Koerts T; Smit JJ; Borst P
Cancer Res; 1990 Mar; 50(6):1779-85. PubMed ID: 1968359
[TBL] [Abstract][Full Text] [Related]
5. PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1.
Spitaler M; Utz I; Hilbe W; Hofmann J; Grunicke HH
Biochem Pharmacol; 1998 Oct; 56(7):861-9. PubMed ID: 9774148
[TBL] [Abstract][Full Text] [Related]
6. Selective modulation of P-glycoprotein-mediated drug resistance.
Bebawy M; Morris MB; Roufogalis BD
Br J Cancer; 2001 Dec; 85(12):1998-2003. PubMed ID: 11747345
[TBL] [Abstract][Full Text] [Related]
7. Improved energy coupling of human P-glycoprotein by the glycine 185 to valine mutation.
Omote H; Figler RA; Polar MK; Al-Shawi MK
Biochemistry; 2004 Apr; 43(13):3917-28. PubMed ID: 15049699
[TBL] [Abstract][Full Text] [Related]
8. Enhanced efflux of [3H]vinblastine from Chinese hamster ovary cells transfected with a full-length complementary DNA clone for the mdr1 gene.
Hammond JR; Johnstone RM; Gros P
Cancer Res; 1989 Jul; 49(14):3867-71. PubMed ID: 2736530
[TBL] [Abstract][Full Text] [Related]
9. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
10. Reduced mRNA levels for the multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines.
Chin KV; Chauhan SS; Abraham I; Sampson KE; Krolczyk AJ; Wong M; Schimmer B; Pastan I; Gottesman MM
J Cell Physiol; 1992 Jul; 152(1):87-94. PubMed ID: 1352302
[TBL] [Abstract][Full Text] [Related]
11. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs.
Willingham MC; Cornwell MM; Cardarelli CO; Gottesman MM; Pastan I
Cancer Res; 1986 Nov; 46(11):5941-6. PubMed ID: 3756931
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.
Lee CG; Gottesman MM; Cardarelli CO; Ramachandra M; Jeang KT; Ambudkar SV; Pastan I; Dey S
Biochemistry; 1998 Mar; 37(11):3594-601. PubMed ID: 9530286
[TBL] [Abstract][Full Text] [Related]
13. Fluorescent verapamil derivative for monitoring activity of the multidrug transporter.
Lelong IH; Guzikowski AP; Haugland RP; Pastan I; Gottesman MM; Willingham MC
Mol Pharmacol; 1991 Oct; 40(4):490-4. PubMed ID: 1681415
[TBL] [Abstract][Full Text] [Related]
14. The inability of the mouse mdr2 gene to confer multidrug resistance is linked to reduced drug binding to the protein.
Buschman E; Gros P
Cancer Res; 1994 Sep; 54(18):4892-8. PubMed ID: 7915194
[TBL] [Abstract][Full Text] [Related]
15. Drugs transported by P-glycoprotein inhibit a 40 pS outwardly rectifying chloride channel.
Bear CE
Biochem Biophys Res Commun; 1994 Apr; 200(1):513-21. PubMed ID: 7909435
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport.
Evers R; Kool M; Smith AJ; van Deemter L; de Haas M; Borst P
Br J Cancer; 2000 Aug; 83(3):366-74. PubMed ID: 10917553
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185----Val-185 substitution in P-glycoprotein.
Safa AR; Stern RK; Choi K; Agresti M; Tamai I; Mehta ND; Roninson IB
Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7225-9. PubMed ID: 1976255
[TBL] [Abstract][Full Text] [Related]
18. P-Glycoprotein kinetics measured in plasma membrane vesicles and living cells.
Aänismaa P; Seelig A
Biochemistry; 2007 Mar; 46(11):3394-404. PubMed ID: 17302433
[TBL] [Abstract][Full Text] [Related]
19. Reversal of multidrug resistance by RU 486.
Gruol DJ; Zee MC; Trotter J; Bourgeois S
Cancer Res; 1994 Jun; 54(12):3088-91. PubMed ID: 7911394
[TBL] [Abstract][Full Text] [Related]
20. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia.
Horio M; Chin KV; Currier SJ; Goldenberg S; Williams C; Pastan I; Gottesman MM; Handler J
J Biol Chem; 1989 Sep; 264(25):14880-4. PubMed ID: 2570070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
